10-K: Forian Reports Strong Revenue Growth, Improved Profitability

Forian Inc. announced a significant increase in revenue and improved net loss for the fiscal year ended December 31, 2025, driven by organic growth and strategic acquisitions.

Summary

• Revenue for the fiscal year ended December 31, 2025, increased by 50.1% to $30,256,919, up from $20,153,263 in 2024.
• The acquisition of Kyber Data Science LLC contributed approximately $6.2 million to the revenue increase.
• Net loss improved to $(2,874,042) in 2025, compared to $(3,771,070) in 2024.
• Adjusted EBITDA increased by 71.8% to $840,408 in 2025, up from $489,134 in 2024.
• Cash and cash equivalents significantly increased to $12,903,760 at year-end 2025 from $4,590,661 at year-end 2024.
• The company fully repaid all outstanding principal and accrued interest on its convertible notes by September 1, 2025.
• A material weakness in internal control over financial reporting related to revenue recognition (ASC 606) was identified as of December 31, 2025, with remediation efforts underway.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. Strong revenue growth and improved profitability metrics are encouraging, but the identified material weakness in internal controls and ongoing data supplier risks warrant careful monitoring.

Positives

• Significant revenue growth of 50.1% year-over-year, driven by both organic expansion and the Kyber acquisition.
• Improved operating loss and net loss, indicating progress towards profitability.
• Adjusted EBITDA saw a substantial increase of 71.8%, reflecting better operational performance.
• Strong increase in cash and cash equivalents, enhancing liquidity.
• Successful repayment of all convertible notes, eliminating associated debt obligations and interest expense.
• Expansion into the financial services market through the Kyber acquisition, diversifying revenue streams.

Negatives

• Gross profit as a percentage of revenues decreased to 53% in 2025 from 64% in 2024, primarily due to higher cost of revenues from the Kyber acquisition and increased information licensing expenses.
• Identified a material weakness in internal control over financial reporting related to the proper application of ASC 606 for revenue recognition.
• Research and development expenses more than doubled, increasing by 101.9% to $2,916,722.
• Sales and marketing expenses increased by 39.2% to $6,034,225.
• Interest and investment income decreased by $1,161,728 due to lower interest rates and a reduced marketable securities balance.

Risks

• The company has a limited operating and financial history and faces risks associated with an early-stage business.
• There is no assurance that additional capital can be raised to fund operations and expansion, and any future equity sales could dilute current stockholders.
• Loss of access to data from external sources, or increased prices for such data, could prevent the company from providing its solutions; one data supplier terminated an agreement in 2024, and another plans to wind down its licensing business by end of 2026.
• Inability to successfully integrate future acquisitions could disrupt operations and adversely impact business and operating results.
• Failure to develop and deploy new products and technologies to address customer needs could harm the business.
• Reliance on third-party computing infrastructure means errors, disruptions, or performance problems could adversely affect operations.
• Inability to successfully manage intellectual property or being subject to infringement claims could negatively impact profitability.
• Real or perceived errors, failures, defects, or bugs in platforms, products, or services could lead to customer terminations and liability.
• Difficulty attracting, recruiting, retaining, and developing qualified employees in a competitive market.
• Material weaknesses in internal control over financial reporting, if not timely remediated, may adversely affect financial statement accuracy and reliability.
• Inability to accurately forecast operating results and growth rate could lead to lower than anticipated results and a decline in stock price.
• Consolidation in customer industries may reduce the volume of services purchased, harming operating results.
• Evolving federal and state privacy and data protection laws could increase operating costs or limit the ability to service customers.
• Security breaches and unauthorized use of systems and information could expose the company to risk of loss and damage its reputation.
• The market price of common stock may be volatile, and stockholders could lose a significant portion of their investment.
• Directors and management own a significant percentage (24.9%) of common stock, enabling them to exert significant control over stockholder-approved matters.
• Forum limitations in the articles of incorporation could limit stockholders' ability to bring claims in preferred jurisdictions.
• Reduced reporting requirements as an emerging growth company and smaller reporting company may make common stock less attractive to investors.
• Increased risk of securities class action litigation following a decline in stock price.

Future Outlook

The company plans to continue investing in commercial sales, research and development, and strategic partnerships. Key elements of its strategy include innovating and advancing its platform and services, driving growth by acquiring new customers, increasing usage and upsell within its existing customer base, leveraging products into new markets such as media and government, expanding its data and strategic partner network, and growing offerings through selective investments and acquisitions.

Management Comments

• Management believes the consolidated financial statements included in this Annual Report on Form 10-K are fairly presented in all material respects in accordance with U.S. GAAP.
• Management is responsible for establishing and maintaining adequate internal control over financial reporting.
• Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets.

Industry Context

StockSavvy.ai notes that Forian operates within the rapidly expanding U.S. healthcare market, which accounts for approximately 17% of GDP. This growth is fueled by an aging population, treatment innovations, and increased digitization of medical records. The company's focus on clinical, commercial, and technology platform analytics aligns with the growing industry need for interoperable and actionable data to enhance commercial effectiveness, manage risk, and improve patient outcomes. The expansion into financial services, particularly serving hedge funds investing in healthcare and biotech, positions Forian to capitalize on the broader alternative data market, where portfolio managers seek deeper proprietary clinical and commercial data.

Comparison to Industry Standards

• Forian competes with established players like ICON plc (information and clinical analytics), IQVIA (information and commercial analytics), Veeva Systems, Inc., and Definitive Healthcare Corp. (technology and services providers).
• The company highlights its 'flexible and scalable approach to privacy-focused analytics software and solutions' and 'deep domain expertise' as competitive strengths, differentiating it from larger incumbents with potentially more rigid systems.
• Forian's 'large integrated longitudinal database and technology' encompassing the vast majority of the U.S. population is a key asset in a market increasingly reliant on comprehensive data sets for longitudinal analyses.

Corporate Governance

Legal Proceedings

• The lawsuit 'Audet v. Green Tree International, et. al.' filed on February 14, 2020, was settled and dismissed with prejudice on March 27, 2024.
• The lawsuit 'Grant Whitus et al. v. Forian Inc., Zachary Venegas and Scott Ogur' filed on July 30, 2021, was settled and dismissed with prejudice on June 7, 2024.

Related Party Transactions

• Adam Dublin, the Chief Strategy Officer, received $24,375 in 2025 and $189,516 in 2024 as runoff commissions from a former vendor, based on a consulting agreement that ended December 11, 2020.
• A director held $6,000,000 of the 3.5% Convertible Promissory Notes until their death on April 11, 2024, after which the notes were held by the spouse of the deceased director. These notes were fully repaid on September 1, 2025.
• The company entered into a customer agreement on September 4, 2024, with an entity controlled by one of its directors, generating revenues of $444,638 in 2025 and $138,092 in 2024.
• The company entered into a vendor agreement on December 23, 2025, with an entity controlled by one of its directors, with aggregate future billings of $750,000.

Stakeholder Impact

• Shareholders: Experience potential dilution from future equity issuances, face market price volatility, and will not receive cash dividends in the foreseeable future. Directors and management hold significant control.
• Employees: Benefit from the company's commitment to equity, fairness, and inclusion. Stock-based compensation is a key incentive, with an increased pool of shares available for awards.
• Customers: Benefit from enhanced information products and analytical solutions designed to optimize operational, clinical, and financial performance. However, they face potential risks from data supplier disruptions or platform errors.
• Data Suppliers: Are critical to the company's offerings, but the company faces risks of suppliers withdrawing data or increasing prices, as evidenced by recent events.
• Creditors: The repayment of all convertible notes by September 1, 2025, reduces the company's debt burden and improves its financial stability from a creditor perspective.

Next Steps

• Continue investing in commercial sales, research and development, and strategic partnerships.
• Innovate and advance the technology platform and services, including releasing new features and upgrades.
• Drive growth by acquiring new customers across existing and new industry verticals.
• Increase usage and upsell additional information solutions within the existing customer base.
• Leverage products into new markets such as media and government.
• Expand the data and strategic partner network, potentially through acquisitions of synergistic assets or companies.
• Remediate the identified material weakness in internal control over financial reporting related to revenue recognition (ASC 606).

Key Dates

Recommendation

Forian Inc. demonstrates strong revenue growth and improved profitability metrics, indicating positive operational momentum. The successful repayment of convertible notes strengthens the balance sheet. However, the identified material weakness in internal controls over revenue recognition and ongoing risks related to data supplier access introduce uncertainty. While the growth trajectory is promising, these internal control and supply chain risks suggest a 'hold' recommendation until remediation efforts are proven effective and data access stability is more assured, allowing for a clearer assessment of long-term sustainable growth.

Keywords

Data Science, Healthcare Analytics, Life Sciences, Financial Services, SEC Filing, 10-K, Annual Report, FORA, Kyber Data Science, Real World Evidence, HIPAA, Data Management, Financial Performance, Corporate Governance